Daub H - Search Results

1

Large-scale proteomics analysis of the human kinome.

Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Kéri G, Mann M, Daub H. Oppermann FS, et al. Among authors: daub h. Mol Cell Proteomics. 2009 Jul;8(7):1751-64. doi: 10.1074/mcp.M800588-MCP200. Epub 2009 Apr 15. Mol Cell Proteomics. 2009. PMID: 19369195 Free PMC article.

2

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H. Godl K, et al. Among authors: daub h. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15434-9. doi: 10.1073/pnas.2535024100. Epub 2003 Dec 10. Proc Natl Acad Sci U S A. 2003. PMID: 14668439 Free PMC article.

3

Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors.

Brehmer D, Godl K, Zech B, Wissing J, Daub H. Brehmer D, et al. Among authors: daub h. Mol Cell Proteomics. 2004 May;3(5):490-500. doi: 10.1074/mcp.M300139-MCP200. Epub 2004 Feb 9. Mol Cell Proteomics. 2004. PMID: 14769951 Free article.

4

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horváth Z, Kéri G, Ullrich A, Daub H. Blencke S, et al. Among authors: daub h. Chem Biol. 2004 May;11(5):691-701. doi: 10.1016/j.chembiol.2004.02.029. Chem Biol. 2004. PMID: 15157880

5

Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.

Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Müller S, Daub H. Wissing J, et al. Among authors: daub h. Mol Cell Proteomics. 2004 Dec;3(12):1181-93. doi: 10.1074/mcp.M400124-MCP200. Epub 2004 Oct 8. Mol Cell Proteomics. 2004. PMID: 15475568 Free article.

6

Cellular targets of gefitinib.

Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, Wissing J, Daub H. Brehmer D, et al. Among authors: daub h. Cancer Res. 2005 Jan 15;65(2):379-82. Cancer Res. 2005. PMID: 15695376

7

Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.

Godl K, Gruss OJ, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Orfi L, Horváth Z, Kéri G, Müller S, Cotten M, Ullrich A, Daub H. Godl K, et al. Among authors: daub h. Cancer Res. 2005 Aug 1;65(15):6919-26. doi: 10.1158/0008-5472.CAN-05-0574. Cancer Res. 2005. PMID: 16061676 Free article.

8

Characterisation of kinase-selective inhibitors by chemical proteomics.

Daub H. Daub H. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):183-90. doi: 10.1016/j.bbapap.2005.07.028. Epub 2005 Sep 12. Biochim Biophys Acta. 2005. PMID: 16198161 Review.

9

Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry.

Wissing J, Jänsch L, Nimtz M, Dieterich G, Hornberger R, Kéri G, Wehland J, Daub H. Wissing J, et al. Among authors: daub h. Mol Cell Proteomics. 2007 Mar;6(3):537-47. doi: 10.1074/mcp.T600062-MCP200. Epub 2006 Dec 27. Mol Cell Proteomics. 2007. PMID: 17192257 Free article.

10

AXL is a potential target for therapeutic intervention in breast cancer progression.

Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A. Zhang YX, et al. Among authors: daub h. Cancer Res. 2008 Mar 15;68(6):1905-15. doi: 10.1158/0008-5472.CAN-07-2661. Cancer Res. 2008. PMID: 18339872

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters